论文部分内容阅读
既往研究表明慢性血透患者长期服用大量氢氧化铝同时给予1-α-羟维生素 D_3能使血浆铝浓度升高。对此有两种可能的机理;小肠对铝的吸收增加或是组织铝储存减少而转运至细胞外液。为了明确何种机理起作用,作者对15例慢性血透患者采用与既往研究相同的剂量(每周6μg)和时间(4周)的1-α-羟维生素 D_3进行研究。病人和方法 15例稳定的慢性血透患者(男10,女5)均无严重的甲状旁腺机能亢进,平均年龄为61.5±14岁,血透持续时间为79±44月。所采用透析液含铝量<0.31μmol/L。所有患者进入研究后,停
Previous studies have shown that patients with chronic hemodialysis long-term use of large amounts of aluminum hydroxide while giving 1-α-hydroxyvitamin D 3 plasma aluminum concentration can be increased. There are two possible mechanisms for this; the intestinal absorption of aluminum increases or the tissue aluminum storage is reduced and transported to the extracellular fluid. In order to clarify which mechanism works, the authors studied 15 patients with chronic hemodialysis using 1-α-hydroxyvitamin D_3 at the same dose (6 μg weekly) and time (4 weeks) as previous studies. Patients and Methods Fifteen patients with stable chronic hemodialysis (male 10, female 5) had no severe hyperparathyroidism with an average age of 61.5 ± 14 years and a hemodialysis duration of 79 ± 44 months. The dialysate used aluminum content <0.31μmol / L. All patients stopped after entering the study